Race to Remission: Timely Diagnosis and Treatment in RA
PROGRAM DESCRIPTION As a 2017 Lancet editorial noted, “Knowing which cytokine and signaling pathways to target in specific individuals is a huge advance, but for a complex progressive, chronic disease ...
As a 2017 Lancet editorial noted, “Knowing which cytokine and signaling pathways to target in specific individuals is a huge advance, but for a complex progressive, chronic disease such as rheumatoid arthritis [RA], the timing of intervention is also critical.” Accordingly, this activity focuses on the need for prompt diagnosis and initiation of treatment for RA, with ongoing assessment and adjustment of therapy in a treat-to-target strategy. All are essential components of the drive to achieve remission or low disease activity and limit the irreversible damage that RA causes.
After completing the activity, the participant should be better able to:Recognize the full spectrum of rheumatoid arthritis (RA) manifestations, including the impact on functional ability, quality of life, and elevated risk for myocardial infarction and strokeDescribe RA pathogenesis and the specific targets of available and emerging disease-modifying antirheumatic drugs (DMARDs)Identify which patients are suitable candidates for targeted DMARDs and determine optimal timing for initiation of DMARD treatmentImplement guidelines-directed, treat-to-target strategies to achieve RA remission or low disease activityIncorporate shared decision-making strategies in RA treatment decisionsIndividualize RA treatment plans with consideration for patient-centric issues such as tolerability and likelihood of adherence in addition to efficacy and safety
I'm interested in this
Share with others
Write the first review
Share with others